Apertura Gene Therapy Licenses TfR1 CapX to Lexeo for FA Program

Apertura Gene Therapy will provide Lexeo Therapeutics access to its IV, BBB-crossing TfR1 CapX AAV capsid for a program designed to treat Friedreich ataxia.Material DetailsContext by AI AnalystThis is an early-stage strategic partnership expanding Apertura’s licensing of its CNS-targeting AAV capsi…